MDL® Isentris® chosen by Ciba Specialty Chemicals as global integration platform for R&D Chemistry Database
State-of-the-art, MDL technology provides Ciba with a solid foundation for their new chemical information system
San Leandro, CA – January 9, 2005 – Elsevier MDL is pleased to announce that Ciba Specialty Chemicals has licensed the MDL® Isentris® information management and integration platform for its global R&D operations. MDL Isentris, is the first out-of-the-box, n-tier discovery informatics platform specifically designed for life sciences and materials researchers.
Martin Weber Nisslé, the Head of R&D Systems, Global Information Services for Ciba Specialty Chemicals stated, “Ciba Specialty Chemicals wants to further strengthen its focus on innovation and fast R&D processes with a new chemical information system that allows global access to a single corporate chemistry database. MDL Isentris will help Ciba implement this deadline-driven project by providing an integration platform for scientific and technical information, both proprietary and from literature.”
“MDL Isentris improves the overall productivity of pharmaceutical and specialty chemical research by enhancing the integration of scientific content and workflow applications,” said Lars Barfod, president and CEO of Elsevier MDL. “State-of-the-art, Isentris technology with its capability of seamlessly migrating chemical information will provide Ciba with a solid foundation for their new chemical information system. We are delighted that Ciba has chosen Isentris.”
The MDL Isentris platform consists of four products: MDL® Base desktop interface for scientists, MDL® Draw chemical drawing software, MDL® Core Interface middle tier for building and integrating Web and desktop applications and MDL® Direct chemical data cartridges for storing, searching and retrieving molecules and reactions in Oracle® databases.
MDL Isentris is the next-generation in cheminformatics technology and the successor to MDL ISIS, which has been the industry-standard for pharmaceutical research for over ten years. Isentris is an open architecture designed to work with in-house applications and third-party tools. Additionally, there is a growing group of companies collaborating via the MDL Isentris Alliance to provide interoperable tools on the Isentris platform.
To learn more about MDL Isentris, contact your Elsevier MDL Account Manager or visit www.mdl.com.
About Elsevier MDL
Elsevier MDL provides informatics, database and workflow solutions that accelerate successful life sciences R&D by improving the speed and quality of scientists’ decision making. Researchers around the world depend on Elsevier MDL for innovative and reliable discovery informatics software solutions and services augmented by 400 Elsevier chemistry and life sciences journals and related products. For more information, visit www.mdl.com. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. For more information visit www.elsevier.com.
Elsevier is part of Reed Elsevier Group plc, a world-leading publisher and information provider. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Elsevier is a global information analytics company that helps institutions and professionals progress science, advance healthcare and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a world-leading provider of information and analytics to professionals and business customers, in a wide range of industries. www.elsevier.com
Dr. Phil McHale
VP, Market & Corporate Communications
Phone: (510) 357-2222 ext. 3541